Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1 Solid Tumor 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1 Kidney Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 14 Injections 13 Paclitaxel 10 Nivolumab 10 Docetaxel 9 Cisplatin 9 Capecitabine 9 Bevacizumab 8 toripalimab 7 senaparib 7 Fluorodeoxyglucose F18 7 Cyclophosphamide 7 tislelizumab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Gemcitabine 5 fludarabine 4 apatinib 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4 Carboplatin 4 spartalizumab 3 sintilimab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × Blood Component Removal × Other solid neoplasm × Clear all

NCT07137312 2025-12-23

Ex Vivo Expansion (ACT-X)

Mayo Clinic

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡